Edwards Lifesciences (EW) Operating Margin (2009 - 2026)

Edwards Lifesciences' Operating Margin history runs 18 years deep, the most recent figure standing at 28.97% for Q1 2026.

• On a quarterly basis, Operating Margin rose 102.0% year-over-year to 28.97% in Q1 2026; TTM through Mar 2026 was 21.37%, a 443.0% decrease from a year earlier, with the FY2025 full-year figure at 20.84%, down 451.0% from the prior year.
• Operating Margin grew to 28.97% in Q1 2026 per EW's latest filing, from 9.63% in the prior quarter.
• Across five years, Operating Margin topped out at 45.99% in Q4 2022 and bottomed at 9.63% in Q4 2025.
• The 5-year median for Operating Margin is 27.38% (2023), against an average of 27.44%.
• Across the five-year window, Operating Margin jumped 1783 bps in 2022 and plunged 1860 bps in 2023, its largest moves.
• Year by year, Operating Margin stood at 45.99% in 2022, then plunged by 40 bps to 27.38% in 2023, then fell by 18 bps to 22.56% in 2024, then sank by 57 bps to 9.63% in 2025, then surged by 201 bps to 28.97% in 2026.
• Per Business Quant, the three latest EW Operating Margin figures stand at 28.97% (Q1 2026), 9.63% (Q4 2025), and 19.77% (Q3 2025).